Tarsus PharmaceuticalsTARS
About: Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Employees: 244
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
63% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 41
4.77% less ownership
Funds ownership: 110.83% [Q1] → 106.06% (-4.77%) [Q2]
5% less funds holding
Funds holding: 156 [Q1] → 148 (-8) [Q2]
24% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 34
28% less capital invested
Capital invested by funds: $1.51B [Q1] → $1.09B (-$422M) [Q2]
43% less funds holding in top 10
Funds holding in top 10: 7 [Q1] → 4 (-3) [Q2]
90% less call options, than puts
Call options by funds: $2.26M | Put options by funds: $22M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Oppenheimer Francois Brisebois 70% 1-year accuracy 21 / 30 met price target | 72%upside $63 | Outperform Reiterated | 9 Aug 2024 |
Financial journalist opinion
Based on 3 articles about TARS published over the past 30 days